Statins in the treatment of hepatitis C

Hepatitis Monthly

Volumn 12, Issue 6, 2012, Pages 40-42

  Vere, Cristin Constantin ^a   Streba, Costin Teodor ^a   Streba, Liliana ^a   Rogoveanu, Ion ^a  

^a UNIVERSITY OF MEDICINE AND PHARMACY OF CRAIOVA   (Romania)

Author keywords

Antiviral; Hepatitis c; Therapy

Indexed keywords

ATORVASTATIN; FLUINDOSTATIN; GERANYLGERANYL PYROPHOSPHATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN RECEPTOR; MEVALONIC ACID; MEVINOLIN; NICOTINIC ACID; PEGINTERFERON; PRAVASTATIN; RIBAVIRIN; SIMVASTATIN;

ARTICLE; CHOLESTEROL SYNTHESIS; DRUG EFFICACY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MONOTHERAPY; VIRUS REPLICATION;

EID: 84864455300     PISSN: 1735143X     EISSN: 17353408     Source Type: Journal    
DOI: 10.5812/hepatmon.845     Document Type: Article

References (20)

1. Liang TJ, Rehermann B, Seeff LB, Hoofnagle JH. Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann Intern Med. 2000;132(4):296-305.
2. Gao B, Hong F, Radaeva S. Host factors and failure of interferonalpha treatment in hepatitis C virus. Hepatology. 2004;39(4):880-90.
3. Ikeda M, Abe K, Yamada M, Dansako H, Naka K, Kato N. Different anti-HCV profiles of statins and their potential for combination therapy with interferon. Hepatology. 2006;44(1):117-25.
4. Forde KA, Law C, O'Flynn R, Kaplan DE. Do statins reduce hepatitis C RNA titers during routine clinical use? World J Gastroenterol. 2009;15(40):5020-7.
5. Ye J, Wang C, Sumpter R, Jr., Brown MS, Goldstein JL, Gale M, Jr. Disruption of hepatitis C virus RNA replication through inhibition of host protein geranylgeranylation. Proc Natl Acad Sci U S A. 2003;100(26):15865-70.
6. Kapadia SB, Chisari FV. Hepatitis C virus RNA replication is regulated by host geranylgeranylation and fatty acids. Proc Natl Acad Sci U S A. 2005;102(7):2561-6.
7. Gibson K, Rindone JP. Experience with statin use in patients with chronic hepatitis C infection. Am J Cardiol. 2005;96(9):1278-9.
8. Khorashadi S, Hasson NK, Cheung RC. Incidence of statin hepatotoxicity in patients with hepatitis C. Clin Gastroenterol Hepatol. 2006;4(7):902-7; quiz 806.
9. Segarra-Newnham M, Parra D, Martin-Cooper EM. Effectiveness and hepatotoxicity of statins in men seropositive for hepatitis C virus. Pharmacotherapy. 2007;27(6):845-51.
10. Delang L, Paeshuyse J, Vliegen I, Leyssen P, Obeid S, Durantel D, et al. Statins potentiate the in vitro anti-hepatitis C virus activity of selective hepatitis C virus inhibitors and delay or prevent resistance development. Hepatology. 2009;50(1):6-16.
11. Harrison SA, Rossaro L, Hu KQ, Patel K, Tillmann H, Dhaliwal S, et al. Serum cholesterol and statin use predict virological response to peginterferon and ribavirin therapy. Hepatology. 2010;52(3):864-74.
12. Bader T, Fazili J, Madhoun M, Aston C, Hughes D, Rizvi S, et al. Fluvastatin inhibits hepatitis C replication in humans. Am J Gastroenterol. 2008;103(6):1383-9.
13. O'Leary JG, Chan JL, McMahon CM, Chung RT. Atorvastatin does not exhibit antiviral activity against HCV at conventional doses: a pilot clinical trial. Hepatology. 2007;45(4):895-8.
14. Andre P, Komurian-Pradel F, Deforges S, Perret M, Berland JL, Sodoyer M, et al. Characterization of low- and very-lowdensity hepatitis C virus RNA-containing particles. J Virol. 2002;76(14):6919-28.
15. Nielsen SU, Bassendine MF, Burt AD, Martin C, Pumeechockchai W, Toms GL. Association between hepatitis C virus and very-lowdensity lipoprotein (VLDL)/LDL analyzed in iodixanol density gradients. J Virol. 2006;80(5):2418-28.
16. Nahmias Y, Goldwasser J, Casali M, van Poll D, Wakita T, Chung RT, et al. Apolipoprotein B-dependent hepatitis C virus secretion is inhibited by the grapefruit flavonoid naringenin. Hepatology. 2008;47(5):1437-45.
17. Corouge M, Pol S. New treatments for chronic hepatitis C virus infection. Med Mal Infect. 2011;41(11):579-87.
18. Kumada H, Toyota J, Okanoue T, Chayama K, Tsubouchi H, Hayashi N. Telaprevir with peginterferon and ribavirin for treatmentnaive patients chronically infected with HCV of genotype 1 in Japan. J Hepatol. 2012;56(1):78-84.
19. Poordad F, McCone J, Jr., Bacon BR, Bruno S, Manns MP, Sulkowski MS, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011;364(13):1195-206.
20. Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med. 2011;364(13):1207-17.